1xbet 모바일 Takeda Pharmaceutical Co., Ltd
1xbet 모바일 Pharmaceutical Co., Ltd.
Pharmaceuticals
May 22, 2020
Launch 1xbet 모바일 Aspirin/Vonoprazan Fumarate Combination Tablets: "Cabpirin®Comb1xbet 모바일ation Tablets"
- Below is a summary English translation provided by 1xbet 모바일 as a reference. The original and full press release in Japanese was issued by Takeda and 1xbet 모바일 on May 22.
1xbet 모바일 Pharmaceutical Co., Ltd. (1xbet 모바일) and Takeda Pharmaceutical Co., Ltd. (Takeda) announce that "Cabpirin®Combination Tablets", a combination 1xbet 모바일 vonoprazan fumarate ("vonoprazan") and low-dose aspirin has been launched.
Under the terms of a domestic co-promotion agreement formed in 2014, Takeda is to manufacture and promote Cabpirin, while promotional activities are to be conducted jointly by 1xbet 모바일 and Takeda.
Takeda submitted to the Ministry 1xbet 모바일 Health, Labor and Welfare an application for manufacturing and marketing approval 1xbet 모바일 this combination tablet in June 2019 and obtained manufacturing and marketing approval on March 25, 2020. The Cabpirin combination tablet contains vonoprazan (also known as a P-CAB), a therapeutic agent for acid-related diseases that has a new mechanism 1xbet 모바일 action, and low-dose aspirin. As such, it is believed that it could improve patient adherence.
Overview 1xbet 모바일Cabpir1xbet 모바일®Comb1xbet 모바일ation Tablets
|
1xbet 모바일dications |
Risk reduction 1xbet 모바일 formation 1xbet 모바일 thrombosis/embolism due to the following disease or after operation (limited to the patients with history 1xbet 모바일 gastric ulcer or duodenal ulcer)
|
||
|---|---|---|---|
| Dosage and adm1xbet 모바일istration |
For adults, an oral dose 1xbet 모바일 one tablet (100 mg/10 mg 1xbet 모바일 aspirin/vonoprazan) is usually administered once a day |
||
| NHI Price |
Cabpir1xbet 모바일® Comb1xbet 모바일ation Tablet 130.3 yen |
||
Latest Pharmaceutical Bus1xbet 모바일ess related News Releases